Premier Comments to FDA on Quality Program for Drug Manufacturing

Dec. 14, 2023
Premier announced it has submitted comments to the Food and Drug Administration on the development of a Quality Management Maturity program

Premier submitted comments to the Food and Drug Administration (FDA) on the development of a Quality Management Maturity (QMM) program. The program aims to improve manufacturing practices and limit drug shortages. Premier agrees with the FDA that more focus on supplier quality incentives and rewards, including payment for reliably meeting providers’ supply requirements, is key to incenting manufacturers to participate in sustainable pharmaceutical markets.

Though, Premier has concerns that a rating system like the QMM may generate unintended downstream consequences that worsen drug shortages and create new operational challenges for U.S. healthcare providers.

Premier has a link to the comments.

Photo 139587 © Daniela Spyropoulou | Dreamstime.com
Photo 7078387 © Marek Uliasz | Dreamstime.com
Photo 139801925 © Mykola Sosiukin | Dreamstime.com